News und Analysen

Oklo’s (NYSE: OKLO) deal with Meta Platforms (NASDAQ: META) is well-liked by the market. Yet another partnership with a major datacenter operator not only affirms the energy technology but also

The S&P 500 and Russell 2000 set new highs in early 2026, indicating not only a rally-on condition but also a bullish outlook for the year. Small caps will be aided by a convergence of factors

2025 was a tumultuous year for digital asset and diversified financial services company Galaxy Digital Holdings Ltd. (NASDAQ: GLXY). Shares dipped below $9 in April and then catapulted to nearly

Shares of Samsara Inc (NYSE: IOT) are starting 2026 at a familiar and increasingly important level. The Internet of Things (IoT) tech stock has once again found support around the $32 mark after

Artificial Intelligence (AI) has hit a physical wall. For the last decade, the primary constraint on technology growth was computing power, or how many chips a company could buy. In 2026, the

For the past two years, the stock market narrative has been dominated by a single theme: infrastructure. Investors watched as major technology companies poured hundreds of billions of dollars into

Stocks had another good week, with all the major indexes poised for weekly gains. This came despite, and perhaps because of, a jobs report that painted a mixed picture about the health of the job

The materials sector doesn't get a lot of love. After finishing last among all 11 S&P 500 sectors in 2024, it mustered a 10% gain last year, which trailed the broad market.  

But as with any

Penguin Solutions (NASDAQ: PENG) could be the deep value AI play you’ve been looking for. It's currently trading at pennies on the dollar relative to long-term forecasts—forecasts that may be

Markets enter 2026 at a crossroads. Oil prices remain subdued but volatile, interest rates are holding steady despite rate-cut hopes, and the S&P 500 continues to climb on the back of strong

The pharmaceutical sector is famously volatile, usually driven by the binary outcomes of clinical trials. A drug either works, sending the stock to the moon, or it fails, causing a crash